Abstract
Advances in the treatment of demented individuals is critically dependent upon experimental administration of new drugs to such people, who, by definition, frequently cannot provide informed consent. Ethical problems associated with studies on demented individuals are therefore of great importance. While there is some similarity to other groups (children, psychotic individuals and patients in coma) there also exist several differences. Obtaining an informed consent from a dementing individual is always problematic. Advance directives are helpful to caregivers and patients should be encouraged, at early stages of the disease, to provide them. Participation in drug studies carries inherent benefits to patients, but at the same time exposes them to risks and discomforts which should be monitored and reviewed more intensively than in studies on cognitively intact individuals. The vulnerability of demented people and their dependence requires special attention by the institutional review board (IRB), unique items to be included in the study protocols and consent forms, etc. Representatives of patients advocacy groups can make important contributions to the IRB, to serve the best interests of the patient and prevent exploitation by the industry as well as by researchers, and honoring the autonomy of the patients. It would be helpful and justified to enable subjects to continue in the study in an open-label design in this situation, once they sign a suitable informed consent. A no-fault insurance could be provided to the patient in this situation.
Keywords: Caregivers, institutional review board, controlled drug trial, dementing people
Current Alzheimer Research
Title: Drug Trials in Dementia: Challenging Ethical Dilemmas
Volume: 4 Issue: 4
Author(s): Amos D. Korczyn
Affiliation:
Keywords: Caregivers, institutional review board, controlled drug trial, dementing people
Abstract: Advances in the treatment of demented individuals is critically dependent upon experimental administration of new drugs to such people, who, by definition, frequently cannot provide informed consent. Ethical problems associated with studies on demented individuals are therefore of great importance. While there is some similarity to other groups (children, psychotic individuals and patients in coma) there also exist several differences. Obtaining an informed consent from a dementing individual is always problematic. Advance directives are helpful to caregivers and patients should be encouraged, at early stages of the disease, to provide them. Participation in drug studies carries inherent benefits to patients, but at the same time exposes them to risks and discomforts which should be monitored and reviewed more intensively than in studies on cognitively intact individuals. The vulnerability of demented people and their dependence requires special attention by the institutional review board (IRB), unique items to be included in the study protocols and consent forms, etc. Representatives of patients advocacy groups can make important contributions to the IRB, to serve the best interests of the patient and prevent exploitation by the industry as well as by researchers, and honoring the autonomy of the patients. It would be helpful and justified to enable subjects to continue in the study in an open-label design in this situation, once they sign a suitable informed consent. A no-fault insurance could be provided to the patient in this situation.
Export Options
About this article
Cite this article as:
Korczyn D. Amos, Drug Trials in Dementia: Challenging Ethical Dilemmas, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788909
DOI https://dx.doi.org/10.2174/156720507781788909 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies
Current Alzheimer Research Tau as a Therapeutic Target for Alzheimers Disease
Current Alzheimer Research Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment
Current Drug Abuse Reviews Novel Indole-Isoxazole Hybrids: Synthesis and In Vitro Anti-Cholinesterase Activity
Letters in Drug Design & Discovery The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design Dampening the Progression of Dementia
Current Neurovascular Research In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds Key Peptides and Proteins in Alzheimer’s Disease
Current Protein & Peptide Science Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease
Current Drug Metabolism Origins, Controversies and Recent Developments of the MCI Construct
Current Alzheimer Research Implication of Complement System and its Regulators in Alzheimers Disease
Current Neuropharmacology Retinoic Acid and the Gut Microbiota in Alzheimer’s Disease: Fighting Back-to-Back?
Current Alzheimer Research End-Stage Dementia Spark of Life: Reliability and Validity of the “GATOS” Questionnaire
Current Alzheimer Research Patent Selections
Recent Patents on DNA & Gene Sequences Structural Changes in Alzheimers Disease Brain Microvessels
Current Alzheimer Research